Jubilant Of India To Buy Draxis Of Canada For $255 Million
This article was originally published in PharmAsia News
Jubilant Organosys of India says it is offering $255 million for Quebec firm Draxis Health as a way to enter the North American market for radiopharmaceuticals. The Draxis board of directors has recommended its shareholders accept the offer. Jubilant said the acquisition would merge two companies specializing in the contract-manufacturing business. In addition, Drasix offers its Draximage radiopharmaceutical division at a time the nuclear isotope business is considered increasingly competitive. (Click here for more
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.